Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)

Öz:

OBJECTIVE The objective of this study was to compare Federation of Gynecology and Obstetrics (FIGO) 2009 and 2018 staging systems in patients with uterine cervical cancer. METHODS Medical records of 571 patients who were treated with adjuvant radiotherapy or radiochemotherapy between 2001 and 2018 were retrospectively reviewed. Differences in overall survival (OS) and progression-free survival (PFS) rates according to FIGO 2009 and FIGO 2018 staging systems were compared using the log-rank test. Cox regression model was used to identify independent prognostic factors for survival. RESULTS The median follow-up was 59 months. Five-year OS and PFS rates were 81.1% and 77.7%, respectively. Stage migration was recorded in 401 patients (70.2%) and the most remarkable stage migration was detected in stage I patients (60%). A total of 157 (27.5%) patients upstaged to stage IIIC disease. According to FIGO 2009, 5-year OS rates were 87.3%, 80.5% (p=0.076), and PFS rates were 82.8%, 77.5% (p=0.036) for stage IB1 and IB2, respectively. According to FIGO 2018, the 5-year OS rates for stage IB1, IB2, and IB3 were 89.8%, 87.1%, and 81.4% (p=0.310), and PFS rates were 90.2%, 80.5%, and 80.1% (p=0.189), respectively. Patients with ≥2 pelvic lymph node (LN) metastases had worse 5-year OS and PFS rates than patients with one metastasis (p=0.015 and p=0.006). Number of para-aortic LN metastasis and metastatic LN ratio (MLNR) were also correlated with 5-year OS and PFS. CONCLUSION Current FIGO staging system better discriminates patients with cervical cancer. However, integration of metastatic LN number and/or MLNR to the upcoming FIGO staging system may improve the prognostic value of the staging.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8(2):e191–e203.
2. International Federation of Gynecology and Obstetrics: FIGO history. Available at: https://www.figo.org/ figo_history. Accessed Nov 22, 2022.
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103–4.
4. Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011;121(2):290–7.
5. Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol 2011;120(3):321–5.
6. Park JY, Joo WD, Chang SJ, Kim DY, Kim JH, Kim YM, et al. Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study. J Surg Oncol 2014;110(3):252–7.
7. Hauerberg L, Høgdall C, Loft A, Ottosen C, Bjoern SF, Mosgaard BJ, et al. Vaginal Radical Trachelectomy for early stage cervical cancer. Results of the Danish National Single Center Strategy. Gynecol Oncol 2015;138(2):304–10.
8. Zhang Q, Li W, Kanis MJ, Qi G, Li M, Yang X, et al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis. Oncotarget 2017;8(28):46580–92.
9. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145(1):129–35.
10. Ooki A, Yamashita K, Kobayashi N, Katada N, Sakuramoto S, Kikuchi S, et al. Lymph node metastasis density and growth pattern as independent prognostic factors in advanced esophageal squamous cell carcinoma. World J Surg 2007;31(11):2184–91.
11. Polterauer S, Hefler L, Seebacher V, Rahhal J, Tempfer C, Horvat R, et al. The impact of lymph node density on survival of cervical cancer patients. Br J Cancer 2010;103(5):613–6.
12. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999;73(2):177–83.
13. Ryu SY, Kim MH, Nam BH, Lee TS, Song ES, Park CY, et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study. Br J Cancer 2014;110(2):278–85.
14. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18(8):1606–13.
15. Small W Jr, Beriwal S, Demanes DJ, Dusenbery KE, Eifel P, Erickson B, et al; American Brachytherapy Society. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012;11(1):58–67.
16. Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol 2019;152(1):87–93.
17. Yan DD, Tang Q, Chen JH, Tu YQ, Lv XJ. Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors. Cancer Manag Res 2019;11:5473–80.
18. Zeng J, Qu P, Hu Y, Sun P, Qi J, Zhao G, et al. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study. Medicine (Baltimore) 2020;99(16):e19714.
19. Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, et al; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A). Gynecol Oncol 2015;137(1):34–9.
20. Inoue T, Okumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer 1984;54(8):1714–9.
21. Hale RJ, Wilcox FL, Buckley CH, Tindall VR, Ryder WDJ, Logueh JP. Prognostic factors in uterine cervical carcinoma: a clinicopathological analysis. Int J Gynecol Cancer 1991;1:19–23.
22. Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer 2012;107(6):918–24.
23. Uno T, Ito H, Itami J, Yasuda S, Isobe K, Hara R, et al. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Anticancer Res 2000;20(3B):2235–9.
24. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S43–103.
25. Dai YF, Xu M, Zhong LY, Xie XY, Liu ZD, Yan MX, et al. Prognostic significance of solitary lymph node metastasis in patients with stages IA2 to IIA cervical carcinoma. J Int Med Res 2018;46(10):4082–91.
26. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990;65(9):1923–7
27. Tsai CS, Lai CH, Wang CC, Chang JT, Chang TC, Tseng CJ, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol 1999;75(3):328–33.
28. Liu X, Wang W, Hu K, Zhang F, Hou X, Yan J, et al. A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System. Sci Rep 2020;10(1):362.
29. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Ohta Y, Fujita M, et al. The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy. Int J Gynecol Cancer 2012;22(3):490–7.
30. Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, et al. The prognosis and risk stratification based on pelvic lymph node characteristics in patients with locally advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. Int J Gynecol Cancer 2016;26(8):1472–9.
31. Kwon J, Eom KY, Kim YS, Park W, Chun M, Lee J, et al. The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors: a multicenter cohort study (KROG 15-04). Cancer Res Treat 2018;50(3):964–74.
32. Hosaka M, Watari H, Mitamura T, Konno Y, Odagiri T, Kato T, et al. Survival and prognosticators of nodepositive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Int J Clin Oncol 2011;16(1):33–8.
33. Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002;81(12):1144–51.
34. Raut A, Chopra S, Mittal P, Patil G, Mahantshetty U, Gurram L, et al. FIGO Classification 2018: Validation study in patients with locally advanced cervix cancer treated with chemoradiation. Int J Radiat Oncol Biol Phys 2020;108(5):1248–56.
35. Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbecks Arch Surg 2016;401(8):1143–52.
36. Yalman D, Demirci S, Bolukbasi Y, Caliskan C, Ozkok S. Postoperative radiotherapy in rectal cancer: longterm results of 290 patients. Hepatogastroenterology 2010;57(102-103):1099–105.
37. Lee CHA, Wilkins S, Oliva K, Staples MP, McMurrick PJ. Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer. BJS Open 2018;3(1):95–105.
38. Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, et al. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol 2015;136(1):48–53.
39. Chen Y, Zhang L, Tian J, Ren X, Hao Q. Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients. Cancer Cell Int 2013;13(1):6.
40. Aslan K, Meydanli MM, Oz M, Tohma YA, Haberal A, Ayhan A. The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy. J Gynecol Oncol 2020;31(1):e1.

APA	alanyali s, Balci B, Beduk Esen C, Gultekin M, akkus yildirim b, özkurt s, Ergen S, GÜRSEL S, ALSAN ÇETIN I, Sert F, Yuce Sari S, Ibis K, Onal C, Sahinler I, Yildiz F, ozsaran z (2023). Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). , 52 - 65. 10.5505/tjo.2022.3822
Chicago	alanyali senem,Balci Beril,Beduk Esen Caglayan Selenge,Gultekin Melis,akkus yildirim berna,özkurt selnur,Ergen Sefika Arzu,GÜRSEL SÜKRIYE BILGE,ALSAN ÇETIN ILKNUR,Sert Fatma,Yuce Sari Sezin,Ibis Kamuran,Onal Cem,Sahinler Ismet,Yildiz Ferah,ozsaran zeynep Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). (2023): 52 - 65. 10.5505/tjo.2022.3822
MLA	alanyali senem,Balci Beril,Beduk Esen Caglayan Selenge,Gultekin Melis,akkus yildirim berna,özkurt selnur,Ergen Sefika Arzu,GÜRSEL SÜKRIYE BILGE,ALSAN ÇETIN ILKNUR,Sert Fatma,Yuce Sari Sezin,Ibis Kamuran,Onal Cem,Sahinler Ismet,Yildiz Ferah,ozsaran zeynep Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). , 2023, ss.52 - 65. 10.5505/tjo.2022.3822
AMA	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). . 2023; 52 - 65. 10.5505/tjo.2022.3822
Vancouver	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). . 2023; 52 - 65. 10.5505/tjo.2022.3822
IEEE	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z "Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)." , ss.52 - 65, 2023. 10.5505/tjo.2022.3822
ISNAD	alanyali, senem vd. "Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)". (2023), 52-65. https://doi.org/10.5505/tjo.2022.3822

APA	alanyali s, Balci B, Beduk Esen C, Gultekin M, akkus yildirim b, özkurt s, Ergen S, GÜRSEL S, ALSAN ÇETIN I, Sert F, Yuce Sari S, Ibis K, Onal C, Sahinler I, Yildiz F, ozsaran z (2023). Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). Türk Onkoloji Dergisi, 38(1), 52 - 65. 10.5505/tjo.2022.3822
Chicago	alanyali senem,Balci Beril,Beduk Esen Caglayan Selenge,Gultekin Melis,akkus yildirim berna,özkurt selnur,Ergen Sefika Arzu,GÜRSEL SÜKRIYE BILGE,ALSAN ÇETIN ILKNUR,Sert Fatma,Yuce Sari Sezin,Ibis Kamuran,Onal Cem,Sahinler Ismet,Yildiz Ferah,ozsaran zeynep Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). Türk Onkoloji Dergisi 38, no.1 (2023): 52 - 65. 10.5505/tjo.2022.3822
MLA	alanyali senem,Balci Beril,Beduk Esen Caglayan Selenge,Gultekin Melis,akkus yildirim berna,özkurt selnur,Ergen Sefika Arzu,GÜRSEL SÜKRIYE BILGE,ALSAN ÇETIN ILKNUR,Sert Fatma,Yuce Sari Sezin,Ibis Kamuran,Onal Cem,Sahinler Ismet,Yildiz Ferah,ozsaran zeynep Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). Türk Onkoloji Dergisi, vol.38, no.1, 2023, ss.52 - 65. 10.5505/tjo.2022.3822
AMA	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). Türk Onkoloji Dergisi. 2023; 38(1): 52 - 65. 10.5505/tjo.2022.3822
Vancouver	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004). Türk Onkoloji Dergisi. 2023; 38(1): 52 - 65. 10.5505/tjo.2022.3822
IEEE	alanyali s,Balci B,Beduk Esen C,Gultekin M,akkus yildirim b,özkurt s,Ergen S,GÜRSEL S,ALSAN ÇETIN I,Sert F,Yuce Sari S,Ibis K,Onal C,Sahinler I,Yildiz F,ozsaran z "Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)." Türk Onkoloji Dergisi, 38, ss.52 - 65, 2023. 10.5505/tjo.2022.3822
ISNAD	alanyali, senem vd. "Restaging of Cervical Cancer Patients Treated with Adjuvant Radiotherapy According to FIGO 2018 and Suggestions for the Next Staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)". Türk Onkoloji Dergisi 38/1 (2023), 52-65. https://doi.org/10.5505/tjo.2022.3822